Navigation Links
Pathway Medical Technologies Names Paul Buckman Chairman of the Board of Directors
Date:3/6/2008

KIRKLAND, Wash., March 6 /PRNewswire/ -- Pathway Medical Technologies, which is developing innovative medical devices for the treatment of arterial disease, announced that Paul Buckman has been named as the new Chairman of the Board of Directors. He replaces Dan Galles, who has been acting Board Chairman since late 2006.

"We are very pleased Paul has accepted the role of Chairman. He brings an extensive range of industry experience to the Pathway board, including early commercialization experience. This is especially important to the company as it prepares for the launch of its first product, the Pathway PV(TM) Artherectomy System," said Galles.

"Since Paul joined our Board in 2007, he has become a real asset. His deep commercial experience with a variety of companies has already proven useful," said Tom Clement, Pathway President and CEO, "and I expect in his new role, Paul's vision and leadership will continue to benefit both the company and the patients who will be treated with our device."

Buckman, who has worked in the medical device industry for over 30 years, is currently CEO and a director of Devax, Inc., a development-stage cardiovascular device company. He joined Devax in 2006 from St. Jude Medical, Inc. where he was an executive officer and President of its Cardiology Division. Before St. Jude Medical, Buckman served as Chairman of the Board of Directors and CEO of ev3, LLC, which he co-founded. Earlier in his career he was with Boston Scientific Corporation, where he held several executive positions before being named President of the Scimed Division, a post he held for 10 years. In the course of his career, Buckman has served on the Board of a variety of companies, including: EndiCor, Inc., Microvena, Inc., Micro Therapeutics, Inc., and Velocimed, Inc., which he also co-founded.

About Pathway Medical Technologies, Inc.

Pathway Medical Technologies, Inc. was founded to design, market and manufacture medical devices for the treatment of arterial disease. The company's initial focus is treating peripheral arterial disease (PAD) more quickly, safely and effectively than existing technologies. An estimated 8-12 million people are afflicted by PAD in the U.S., and that number is projected to grow to over 20 million during the next 10 years. The company's Pathway PV(TM) Atherectomy System allows for a minimally invasive procedure designed to restore circulation in the peripheral arteries by removing both hard and soft diseased tissue. For further information, visit the company's Web site at http://www.pathwaymedical.com.


'/>"/>
SOURCE Pathway Medical Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genetic pathway critical to disease, aging found
2. AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test
3. Pathway Diagnostics Announces Patent Issuance for the Diagnostic Measurement of HIV Tropism for the Initiation or Modification of HIV Therapy
4. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
5. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
6. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
7. Major Medical Journal Reports Higher Success, Fewer Complications and Lower Cost Treating DVT With Trellis(R) Isolated Thrombolysis Compared With Catheter-Directed Thrombolysis
8. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target
9. LifeNet Health(R) Unveils New Biomedical Spine Implant
10. IMPAC Medical Systems and Aperio to Develop Integrated Solution for Anatomic Pathology
11. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... 2016 A person commits a crime, and the ... track the criminal down. An outbreak of foodborne ... Administration (FDA) uses DNA evidence to track down the bacteria ... far-fetched? It,s not. The FDA has increasingly used a complex, ... foodborne illnesses. Put as simply as possible, whole genome sequencing ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
Breaking Biology Technology:
(Date:6/20/2016)... , June 20, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... prisons involved, it has secured the final acceptance ... facilities for Managed Access Systems (MAS) installed. Furthermore, ... facilities to be installed by October, 2016. MAS ...
(Date:6/9/2016)... -- Perkotek an innovation leader in attendance control systems is proud to announce the introduction ... to make sure the right employees are actually signing in, and to even control ... ... ... ...
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
Breaking Biology News(10 mins):